Compare PHR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHR | NEO |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.2M | 1.6B |
| IPO Year | 2019 | 2008 |
| Metric | PHR | NEO |
|---|---|---|
| Price | $12.26 | $9.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $30.65 | $11.14 |
| AVG Volume (30 Days) | ★ 2.0M | 1.8M |
| Earning Date | 03-09-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.36 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $419,813,000.00 | N/A |
| Revenue This Year | $15.56 | $10.53 |
| Revenue Next Year | $15.08 | $9.25 |
| P/E Ratio | $614.75 | ★ N/A |
| Revenue Growth | ★ 17.83 | N/A |
| 52 Week Low | $11.31 | $4.72 |
| 52 Week High | $32.76 | $13.74 |
| Indicator | PHR | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 29.87 |
| Support Level | $11.58 | $9.13 |
| Resistance Level | $12.79 | $11.02 |
| Average True Range (ATR) | 0.64 | 0.65 |
| MACD | 0.18 | -0.11 |
| Stochastic Oscillator | 64.19 | 9.18 |
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.